000363312 001__ 363312
000363312 005__ 20260124173032.0
000363312 0247_ $$2CORDIS$$aG:(EU-Grant) 101124542$$d101124542
000363312 0247_ $$2CORDIS$$aG:(EU-Call)ERC-2023-COG$$dERC-2023-COG
000363312 0247_ $$2originalID$$acorda__h2020::101124542
000363312 0247_ $$2doi$$a10.3030/101124542
000363312 035__ $$aG:(EU-Grant)101124542
000363312 150__ $$a
Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies
$$y2024-04-01 - 2029-03-31
000363312 372__ $$aERC-2023-COG$$s2024-04-01$$t2029-03-31
000363312 450__ $$aRewind-MF$$wd$$y2024-04-01 - 2029-03-31
000363312 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000363312 680__ $$a
Is it possible to reverse fibrosis? When there is injury or damage to an organ, the normal healing process involves the formation of new tissue. When this process becomes dysregulated, it leads to the formation of excessive fibrous connective tissue causing fibrosis. Funded by the European Research Council, the Rewind-MF project focuses on primary myelofibrosis, a blood malignancy associated with the activation of fibrosis-driving cells in the bone marrow. The study explores the reversibility of fibrosis, particularly in cases where allogeneic stem cell transplantation is not a viable option. By delving into the mechanisms of reversing fibrosis, researchers expect to identify therapeutic targets and understand how blood cancer is sustained in the bone marrow.

000363312 909CO $$ooai:publications.rwth-aachen.de:1022762$$pauthority$$pauthority:GRANT
000363312 909CO $$ooai:publications.rwth-aachen.de:1022762
000363312 909CO $$ooai:publications.rwth-aachen.de:1022762
000363312 980__ $$aG
000363312 980__ $$aCORDIS
000363312 980__ $$aAUTHORITY